Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325416 · ClinicalTrials.gov registry record · Phase 1
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 177
- Enrollment target
NCT00325416 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 177 participants.
The verdict
NCT00325416, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 177 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the safest dose of topotecan when given in a high dose before a stem cell transplant; topotecan will be given with melphalan.
Interventions
- DRUG melphalan
- PROCEDURE Autologous Stem Cell Rescue
- DRUG topotecan (TPT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2001-11-19 |
| Est. Completion | 2018-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00325416
The ClinicalTrials.gov registry entry for NCT00325416 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which melphalan is the first listed.
NCT00325416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00325416 about?
NCT00325416 is a clinical study titled "Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.". The purpose of this research study is to determine the safest dose of topotecan when given in a high dose before a stem cell transplant; topotecan will be given with melphalan.
What is the current status of trial NCT00325416?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2001-11-19. Estimated completion is 2018-01-30.
What interventions are being tested in trial NCT00325416?
The interventions under investigation include: melphalan (DRUG), Autologous Stem Cell Rescue (PROCEDURE), topotecan (TPT) (DRUG).
Who is sponsoring clinical trial NCT00325416?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.